ClinicalTrials.Veeva

Menu

Presepsin as Detective Marker of Sepsis in Immunodeficiency ICU Patients (PREICU)

J

Jongmin Lee

Status

Completed

Conditions

Immune Deficiency
Sepsis

Study type

Observational

Funder types

Other

Identifiers

NCT03881566
PRESEPSIN_IMMUNODIFFICIENCY

Details and patient eligibility

About

This is an observational study to evaluate the diagnostic and prognostic value of presepsin in the critically-ill immunocompromise patients.

Enrollment

119 patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female aged ≥ 19 years
  • Appropriate clinical data to enable classification into sepsis
  • Written informed consent by the patient or legally authorized representative
  • Critical illness consistent with sepsis, to be enrolled within 24 hours of presentation

Exclusion criteria

  • No informed consent
  • A patient who is judged to be unable to make a voluntary decision by understanding information about this research due to cognitive vulnerability

Trial design

119 participants in 3 patient groups

Immunocompetent sepsis patients
Description:
Sepsis patients without HIV infection (all stages), neutropenia (neutrophil count \< 1 × 109/L), exposure to glucocorticoids (\> 0.5 mg/kg for \> 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.
Immunocompromised sepsis patients
Description:
Sepsis patients with HIV infection (all stages), neutropenia (neutrophil count \< 1 × 109/L), exposure to glucocorticoids (\> 0.5 mg/kg for \> 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.
Patients without sepsis
Description:
Patients who admitted intensive care unit without sepsis

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems